Early Chagas’ heart disease in the Ecuadorian Amazon. Treatment and outcome of a clinical case

Authors

  • Manuel Amunárriz Universidad de Guayaquil

DOI:

https://doi.org/10.53591/rug.v115i1.473

Keywords:

Heart disease, Chagas, Nifurtimox, Amazon, Ecuador

Abstract

Objective: This is a case of early chagasic heart disease in a 9-year-old boy, identified by the initials JCV, with the evolution of the condition after the treatment was established. Methods: The methods employed in the diagnosis and monitoring of this case are set out as follows: basic laboratory, chest X-rays with the cardiothoracic index, electrocardiogram and determination of the PR and of the QTcintervals and echocardiograms and ELISA tests to determine chagasic antibody levels. The therapeutic criteria are outlined, with Nifurtimox: 12 milligrams per kilo a day for a time period of 120 days, and supportive therapies. Results: The results obtained over the successive stages of the condition are described. Within a period of four months, the cardiothoracic index became normal; the first-degree atrioventricular block disappeared; alterations in the ventricular repolarisation returned to normal values; antibody titers detected by ELISA tests went below the cut-off point. Conclusions: A good result was observed with the established therapy with Nifurtimox, without adverse reactions in the patient. The data obtained suggest the existence of childhood chagasic heart disease of recent origin, with full recovery likely. The patient needs to be monitored at both immunological and echocardiographic levels over a long time period in order to confirm the results obtained.

References

Amunárriz, M. Enfermedad de Chagas; primer foco amazónico. Estudios sobre Patologías Tropicales en la Amazonia Ecuatoriana. Pompeya. Ecuador: CICAME; 1991.p. 27-36.

Amunárriz M, Chico ME, Guderian RH. Chagas disease in Ecuador; a sylvatic focus in Amazon Region. J Trop Med Hyg. 1991;94: 145-9.

Chico M, Sandoval C, Guevara A, Calvopiña M, Cooper PJ, Reed SG, et al. Chagas disease in Ecuador: evidence for disease transmission in an indigenous population in the Amazon region. MemInstOswaldoCruz.1997; 92 (3):317-20.

Grijalva MJ, Escalante L, Paredes RA, Costales JA, Padilla A, Rowland EC, et al Seroprevalence and risk factors for Tripanosomacruzi infection in the Amazon region of Ecuador. Am J MedHyg. 2003;69(4):380-5.

Amunárriz M, Quito S, Tandazo V, López M. Seroprevalencia de la enfermedad de Chagas en el cantón Aguarico, Amazonia ecuatoriana. RevPanam Salud Pública. 2010; 28(1):25–9.

Amunárriz M, Quito S, TandazoV. Terapia de la enfermedad de Chagas en el cantón Aguarico, Amazonia ecuatoriana. Rev Universidad Guayaquil. 2011; 111:23-9.

The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection. N Engl J Med. 1992; 327: 685-91.

Elizari M. La miocardiopatía chagásica. Perspectiva histórica. Medicina. 1999;59(sup II): 25-40.

Salles G, Xavier SS, Sousa AS, Hasslocher-Moreno A, Cardoso C. Prognostic value of QT interval parameters for mortality risk stratification in Chagas’ disease. Results of a long-term follow-up study. Circulation. 2003;108:305-12.

Elizari MV. Enfermedad del nódulo sinusal en la enfermedad de Chagas. RevFedArgCardiol. 1988;17:205-12.

Mengel JO, Rossi MA. Chronic chagasic myocarditis pathogenesis: dependence on autoimmune and microvascular factors. Am Heart J. 1992; 124:1052-7.

Rossi MA, Mengel JO.Patogenese da miocarditechagasicacronica: o papel de factores autoinmunes e microvasculares. RevInstMedTropSao Paulo. 1992; 34:593-9.

Barbosa AJA, Pittella JEM, Tafuri WL. Incidênca de cardiopatía chagásicaem 15.000 necrópsias consecutivas e suaassociaçãocom os “megas”. RevSocBrasMedTrop. 1970;4:219-23.

Andrade ZA, Andrade SG, Oliveira GB, Alonso DR. Histopathology of the conducting tissue of the heart in Chagas´myocarditis. Am Heart J. 1978; 95:316-24.

Gascón J,Albajar P, Cañas E, Flores M, Gómez i Prat J, Herrera R, et al. Diagnóstico, manejo y tratamiento de la cardiopatía chagásica crónica en áreas donde la infección por Trypanosomacruzi no es endémica. EnfermInfeccMicrobiolClin. 2008; 26(02):99-106.

Dávila-Spinetti DF, Colmenarez-Mendoza HL, Lobo-Vielma L. Mecanismos causantes de la progresión del daño miocárdico en la enfermedad de Chagas crónica. RevEspCardiol. 2005; 58:1007-9.

Guedes PM, Silva GK, Gutierrez FR, Silva JS. Current status of Chagasdesease chemotherapy. Expert Rev Anti Infect Ther. 2011; 9(5):609-20.

Gallerano RH, Sosa RR. Resultados de un estudio a largo plazo con drogas antiparasitarias en infectados chagásicos crónicos. RevFedArgCardiol. 2001; 30:289-96.

Fabbro DL, Arias ED, Streiger ML, Del Barco ML, Amicone N, Miglietta H. Evaluación de la quimioterapia específica en infectados chagásicos adultos en fase indeterminada con más de quince años de seguimiento. RevFedArgCardiol. 2001; 30: 496-503.

Apt W. Tratamiento de la enfermedad de Chagas. Parasitol día. 1999; 23:3-4.

Apt BW, Heitmann GI, Jercic LMI, Jotré ML, Muñoz C. del V P, Noemí HI, et al. Tratamiento antiparasitario de la enfermedad de Chagas. RevChilInfect. 2008; 25(5):384-9.

Viotti R, Vigliano C, Lococo B, Bertocchi G, Petti M, Álvarez MG, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment. Ann IntMed. 2006; 144:724-34.

Published

2013-01-07

How to Cite

Amunárriz, M. (2013). Early Chagas’ heart disease in the Ecuadorian Amazon. Treatment and outcome of a clinical case. Revista Universidad De Guayaquil, 115(1), 27–36. https://doi.org/10.53591/rug.v115i1.473

Issue

Section

Research Articles

Similar Articles

1 2 3 4 5 6 7 8 9 10 > >> 

You may also start an advanced similarity search for this article.